Optimistic IPO Outlook For Biopharma Fueled By Early Trends

 
• By Jessica Merrill

The US market for biopharma initial public offerings is expected to return to a more normal level in 2024, according to experts at the BIO CEO & Investor Conference.

IPO
Experts at BIO CE& & Investor discussed the IPO market outlook. • Source: Shutterstock

More from Financing

More from Business